NasdaqCM - Delayed Quote USD
Avenue Therapeutics, Inc. (ATXI)
At close: November 1 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Alexandra MacLean M.D. | CEO & Director | 413.2k | -- | 1967 |
Mr. David Jin | Interim CFO, COO & Corporate Secretary | -- | -- | 1990 |
Dr. Lindsay Allan Rosenwald | Executive Director | -- | -- | 1955 |
Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer | 69.12k | -- | 1947 |
Avenue Therapeutics, Inc.
1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 3
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Corporate Governance
Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 11, 2024 at 10:59 AM UTC - November 15, 2024 at 12:00 PM UTC
Avenue Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
FBIO Fortress Biotech, Inc.
1.9000
0.00%
ALLR Allarity Therapeutics, Inc.
1.3800
-1.43%
CKPT Checkpoint Therapeutics, Inc.
3.5100
+2.03%
ABVC ABVC BioPharma, Inc.
0.6600
-4.49%
PALI Palisade Bio, Inc.
2.7700
+1.84%
SXTP 60 Degrees Pharmaceuticals, Inc.
0.7828
+1.53%
ADTX Aditxt, Inc.
0.5299
-4.52%
APVO Aptevo Therapeutics Inc.
0.2480
-8.11%
PCSA Processa Pharmaceuticals, Inc.
1.1500
-0.43%
DRMA Dermata Therapeutics, Inc.
1.2250
-3.54%